-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The nine-valent HPV vaccine has been in the public eye for more than 3 years, but the situation that a vaccine is difficult to find is still frequently reported, and the vaccine reservation system online in various places has also received a lot of complaints
.
Why is a 9-valent HPV vaccine hard to find? When will the tight supply ease? Qiao Youlin, a professor of the School of Medicine and Public Health of the Peking Union Medical College and a member of the WHO Director-General's Cancer Prevention and Treatment Expert Group, accepted an interview with a reporter from CCTV
.
Qiao Youlin said that at present, the reason why the HPV vaccine is difficult to obtain is the imbalance between supply and demand
.
Previously, overseas vaccines had to be clinically tested in China before they entered China.
Imported bivalent and quadrivalent HPV vaccines have been waiting for 8 years
.
In 2016, GlaxoSmithKline’s bivalent HPV vaccine Cerexis obtained the marketing license of the State Food and Drug Administration, becoming the first domestically approved HPV vaccine to prevent cervical cancer.
It was launched overseas in 2006
.
In 2017, Merck’s quadrivalent HPV vaccine was also approved for domestic marketing after 8 years of clinical trials
.
However, in 2018, the National Medical Products Administration received the nine-valent HPV vaccine import registration application and conditionally approved the listing of Merck’s nine-valent HPV vaccine in just 9 days
.
"Vaccine manufacturers never expected that China's 9-valent vaccine would be available within 9 days.
Therefore, its production plan was not arranged at all.
It was suddenly approved.
In order to meet the needs of mainland China, they reduced the quotas of other countries.
In order to guarantee China’s supply, it is still not enough
.
” And “the market has accumulated 10 years of consumer demand”
.
In overseas markets, the people have gone through a long waiting process from the second price and the fourth price to the nine price.
However, in China, “the second price and the fourth price have not yet become popular, and the nine price is coming soon.
The price is scarce"
.
Qiao Youlin revealed, “Nine-valent vaccine production company Merck & Co.
is also increasing its production capacity and will substantially increase its supply to China next year
.
There are more than 10 pharmaceutical factories in our country that are making HPV vaccines, so in the next few years Within this period, vaccines will continue to be introduced to the market.
By that time, vaccines will be covered throughout the entire process.
This is not a big problem.
"
.
Qiao Youlin emphasized that when there is still a shortage of vaccine supply, it is still necessary to vaccinate the most protected and best immune girls under the age of 15
.
.
Why is a 9-valent HPV vaccine hard to find? When will the tight supply ease? Qiao Youlin, a professor of the School of Medicine and Public Health of the Peking Union Medical College and a member of the WHO Director-General's Cancer Prevention and Treatment Expert Group, accepted an interview with a reporter from CCTV
.
Qiao Youlin said that at present, the reason why the HPV vaccine is difficult to obtain is the imbalance between supply and demand
.
Previously, overseas vaccines had to be clinically tested in China before they entered China.
Imported bivalent and quadrivalent HPV vaccines have been waiting for 8 years
.
In 2016, GlaxoSmithKline’s bivalent HPV vaccine Cerexis obtained the marketing license of the State Food and Drug Administration, becoming the first domestically approved HPV vaccine to prevent cervical cancer.
It was launched overseas in 2006
.
In 2017, Merck’s quadrivalent HPV vaccine was also approved for domestic marketing after 8 years of clinical trials
.
However, in 2018, the National Medical Products Administration received the nine-valent HPV vaccine import registration application and conditionally approved the listing of Merck’s nine-valent HPV vaccine in just 9 days
.
"Vaccine manufacturers never expected that China's 9-valent vaccine would be available within 9 days.
Therefore, its production plan was not arranged at all.
It was suddenly approved.
In order to meet the needs of mainland China, they reduced the quotas of other countries.
In order to guarantee China’s supply, it is still not enough
.
” And “the market has accumulated 10 years of consumer demand”
.
In overseas markets, the people have gone through a long waiting process from the second price and the fourth price to the nine price.
However, in China, “the second price and the fourth price have not yet become popular, and the nine price is coming soon.
The price is scarce"
.
Qiao Youlin revealed, “Nine-valent vaccine production company Merck & Co.
is also increasing its production capacity and will substantially increase its supply to China next year
.
There are more than 10 pharmaceutical factories in our country that are making HPV vaccines, so in the next few years Within this period, vaccines will continue to be introduced to the market.
By that time, vaccines will be covered throughout the entire process.
This is not a big problem.
"
.
Qiao Youlin emphasized that when there is still a shortage of vaccine supply, it is still necessary to vaccinate the most protected and best immune girls under the age of 15
.